Craft

Edwards Lifesciences

Stock Price

$91

2024-07-12

Market Capitalization

$54.8 B

2024-07-12

Revenue

$6 B

FY, 2023

Edwards Lifesciences Summary

Company Summary

Overview
Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring. It offers transcatheter aortic valve replacement technologies for minimally invasive replacement of aortic heart valves, transcatheter mitral and tricuspid therapies designed to treat mitral and tricuspid valve diseases, cardiac surgical therapies, and hemodynamic monitoring systems.
Type
Public
Status
Active
Founded
1958
HQ
Irvine, CA, US | view all locations
Website
https://www.edwards.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Bernard J. Zovighian

    Bernard J. Zovighian, Chief Executive Officer and Director

  • Scott B. Ullem

    Scott B. Ullem, Corporate Vice President, Chief Financial Officer

  • Todd J. Brinton

    Todd J. Brinton, Corporate Vice President, Advanced Technology, Chief Scientific Officer

  • Dirksen J. Lehman

    Dirksen J. Lehman, Corporate Vice President, Public Affairs

Operating MetricsView all

Countries

100

FY, 2022

Manufacturing Facilities

7

FY, 2022

LocationsView all

41 locations detected

  • Irvine, CA HQ

    United States

    1 Edwards Way

  • Draper, UT

    United States

    12050 Lone Peak Pkwy

  • Washington, DC

    United States

    601 13th St NW #350

  • Macquarie Park, NSW

    Australia

    40 Talavera Rd

  • Wien, Wien

    Austria

    Vorgartenstraße 206C

  • Dilbeek, Vlaanderen

    Belgium

    Pontbeekstraat 4

and 35 others

Edwards Lifesciences Financials

Summary Financials

Revenue (Q1, 2024)
$1.6B
Gross profit (Q1, 2024)
$1.2B
Net income (Q1, 2024)
$351.0M
Cash (Q1, 2024)
$1.2B
EBIT (Q1, 2024)
$387.5M
Enterprise value
$54.2B

Footer menu